Mast Cell Activation Syndrome and Beta-Caryophyllene: What Does the Research Show?

What happens when an immune cell releases its chemical signals at the wrong time?
For people experiencing mast-cell activation, the effects can involve several parts of the body at once. Flushing, itching, abdominal discomfort, breathing symptoms and changes in blood pressure can appear during the same episode.
Researchers are investigating how mast cells regulate the release of inflammatory mediators and whether particular plant compounds can influence that process.
One compound attracting attention is beta-caryophyllene (BCP), a naturally occurring terpene found in cloves, black pepper and other aromatic plants.
In a 2021 experimental study, scientists observed that BCP reduced mast-cell degranulation and histamine release in laboratory preparations and altered anaphylaxis-like responses in animals.
The finding raises an important scientific question: Could the signaling pathways influenced by BCP help researchers better understand mast-cell activation?
What Is MCAS?
Mast cell activation syndrome (MCAS) is a disorder characterized by recurrent episodes of excessive mast-cell mediator release that produce systemic symptoms.
Mast cells are immune cells distributed throughout the body, including the skin, airways, gastrointestinal tract and tissues surrounding blood vessels and nerves.
Under normal circumstances, they respond to threats and help coordinate protective immune activity.
When activated, mast cells release chemical messengers known as mediators. Histamine is the best-known example, but mast cells also produce or release prostaglandins, leukotrienes, proteases and cytokines.
These substances act on different tissues. Their combined effects help explain why mast-cell activation can produce symptoms that initially seem unrelated.
MCAS is a specific clinical diagnosis, rather than a general description of any unexplained symptoms involving histamine.
Why Mast Cells Matter
A mast cell contains granules filled with preformed chemical mediators.
When a suitable trigger activates the cell, it can release granule contents into surrounding tissues. This process is called degranulation.
Some mast-cell responses are initiated through immunoglobulin E (IgE), the antibody involved in many allergic reactions.
Others occur through different receptor systems and cellular signaling pathways.
This distinction matters because a substance that modifies one route of mast-cell activation may behave differently when another route is involved.
The body also regulates newly synthesized mediators, including lipid-derived compounds and inflammatory cytokines.
That means mast-cell biology involves several interconnected processes: recognition of a trigger, intracellular signaling, mediator synthesis, granule release and the effects of those mediators on nearby tissues.
Each process gives researchers a different biological question to investigate.

Histamine and Other Mediators
Histamine can affect blood vessels, smooth muscle, sensory nerves and the gastrointestinal tract.
Its actions help explain the flushing, itching, swelling and gastrointestinal symptoms associated with mast-cell activation.
Other mediators contribute different effects.
Leukotrienes participate in inflammatory signaling and can influence airway narrowing.
Prostaglandins affect blood vessels and several inflammatory processes.
Tryptase is a mast-cell-associated enzyme that can be measured clinically and is particularly important in evaluating suspected systemic mast-cell activation.
Cytokines help coordinate interactions among immune cells and may contribute to the broader inflammatory response.
The clinical effects depend on which mediators are released, their concentrations, the tissues involved and the characteristics of the individual response.
This is why mast-cell activation cannot be understood through histamine alone.
MCAS Symptoms and Triggers
Systemic mast-cell activation can affect several organ systems during the same episode.
Possible manifestations include flushing, hives, itching, abdominal cramping, diarrhea, wheezing, swelling, lightheadedness and low blood pressure.
Severe episodes may involve anaphylaxis.
Triggers vary among patients and can include foods, medications, temperature changes, physical exertion, infections and other exposures.
Identifying a suspected trigger is one part of the clinical evaluation. Symptoms alone, however, cannot establish MCAS, because allergic conditions and several other disorders can produce overlapping presentations.
Anaphylaxis requires immediate emergency treatment with epinephrine. Investigational nutritional compounds are not substitutes for that treatment.
How MCAS Is Diagnosed
Internationally used consensus criteria emphasize three findings.
First, patients experience recurrent, severe systemic episodes consistent with mast-cell mediator release, typically involving at least two organ systems.
Second, clinicians obtain objective evidence of mediator elevation during an episode.
A commonly used serum tryptase criterion requires an event-related increase above the individual's baseline by at least 20% plus 2 ng/mL. Urinary measurements of selected mast-cell mediators may also contribute to evaluation.
Third, symptoms respond to medication that blocks mediator effects or suppresses mast-cell activation.
A clinical investigation also considers other explanations, including allergic reactions and clonal mast-cell disorders.
A 2025 Canadian clinical review describes a practical diagnostic approach involving symptom patterns, mediator measurements, evaluation of alternative causes and individualized management.
Research: Lee et al., 2025. Diagnosis and management of MCAS in Canada: a practical approach.
Beta-Caryophyllene and CB2
Beta-caryophyllene is a bicyclic sesquiterpene naturally present in several culinary and aromatic plants.
Its pharmacology attracted particular attention after a 2008 study demonstrated that BCP binds to and activates the cannabinoid type 2 receptor, commonly called CB2.
CB2 is associated with immune-cell signaling and inflammatory regulation.
In the original receptor study, researchers investigated BCP in cellular experiments and mouse models. They observed CB2-dependent effects on selected inflammatory responses.
This finding established an important molecular mechanism for BCP research.
It also provides a reason to investigate whether the compound influences other immune processes, including mast-cell activity.
The receptor finding and the mast-cell experiments are related areas of research, but they should be distinguished: demonstrating that BCP activates CB2 does not establish that every later effect of BCP is caused by CB2.
Research: Gertsch et al., 2008. Beta-caryophyllene is a dietary cannabinoid.
What the Mast-Cell Study Found
A particularly relevant experiment was published by Pathak and colleagues in Clinical and Experimental Pharmacology and Physiology in 2021.
The researchers investigated beta-caryophyllene in models of pseudo-allergic mast-cell activation.
They used compound 48/80, a laboratory substance that can stimulate mast-cell responses through an IgE-independent mechanism.
The investigation included isolated rat peritoneal mast cells, mice subjected to systemic and cutaneous anaphylaxis-like challenges, and rats used to examine changes in arterial blood pressure.
Several findings emerged.
Mast-cell degranulation decreased. In the isolated cell experiments, BCP inhibited degranulation in a concentration-dependent manner.
Histamine release decreased. The investigators reported reduced histamine release alongside the changes in degranulation.
Anaphylaxis-like responses were modified. In the animal experiments, BCP reduced measured systemic and skin responses induced by compound 48/80.
Cellular signaling changed. The study identified effects involving adiponectin receptors AdipoR1 and AdipoR2 and the Nrf2/HO-1 signaling pathway.
These findings are important because they connect BCP exposure with measurable mast-cell behavior rather than relying solely on its established CB2 receptor activity.
The investigators' central mechanistic proposal involved adiponectin receptor and Nrf2/HO-1 signaling.
Their results did not establish that the observed suppression of degranulation depended on CB2.
Nor did the experiments administer BCPlus to patients with MCAS.
Research: Pathak et al., 2021. Crosstalk between AdipoR1/AdipoR2 and Nrf2/HO-1 signal pathways activated by β-caryophyllene.

Why Nrf2 and Adiponectin Matter
The Nrf2 pathway participates in cellular responses to oxidative and electrophilic stress.
When activated, Nrf2 can influence expression of proteins involved in maintaining cellular redox balance. Heme oxygenase-1, or HO-1, is one of the proteins commonly studied in this pathway.
AdipoR1 and AdipoR2 are receptors associated with adiponectin signaling and metabolic regulation.
In the Pathak experiment, investigators examined changes in both receptor-related and Nrf2/HO-1 signaling markers following BCP exposure.
Their observations suggest that BCP may influence mast-cell responses through several interconnected cellular pathways.
This creates an interesting distinction between two research findings:
BCP is an experimentally characterized CB2 agonist.
BCP has also been observed to influence mast-cell degranulation through pathways investigated in the 2021 pseudo-allergy study.
Understanding how these mechanisms interact is an open scientific question.

What Does This Mean for MCAS?
The strongest directly relevant evidence identifies BCP as a compound capable of modifying particular mast-cell responses in experimental systems.
That is useful mechanistic evidence.
Whether those effects occur at achievable human tissue concentrations, persist with repeated exposure, or alter the course of clinically diagnosed MCAS remains to be determined.
MCAS involves heterogeneous clinical presentations, and the compound 48/80 model examines one defined route of mast-cell activation.
The distinction is particularly relevant when interpreting research on allergic and pseudo-allergic reactions.
Results obtained through an IgE-independent experimental trigger do not automatically establish equivalent effects during IgE-mediated allergic reactions.
Likewise, experimentally reduced anaphylaxis-like responses in animals are not evidence that BCP can prevent or treat anaphylaxis in humans.
The scientific value of the findings lies in identifying biological mechanisms that can be tested more precisely.
Current MCAS Management
Clinical management generally focuses on identifying relevant triggers, investigating the underlying mast-cell disorder and controlling mediator-related symptoms.
Depending on the patient and presentation, physicians may use H1 or H2 antihistamines, mast-cell stabilizers, leukotriene-directed medications and other individualized approaches.
For patients at risk of anaphylaxis, emergency epinephrine and an appropriate action plan are essential.
The specific treatment strategy depends on the clinical diagnosis, history and response to therapy.
Nutrition and trigger management may be individualized, but current evidence does not support one universally effective low-histamine diet for MCAS.
BCP remains a research subject within this clinical context.
Clinical references:
The Next Research Questions
The existing findings support several specific questions for future investigation.
One is whether similar reductions in mediator release occur in human mast-cell preparations under clinically relevant activation conditions.
Another is which signaling pathways are necessary for those effects.
CB2, adiponectin receptor signaling and Nrf2/HO-1 activity can be studied individually and in combination to determine their respective contributions.
Researchers must also examine exposure, metabolism and formulation. BCP is a lipophilic compound, so the delivery format may influence how much reaches different tissues.
Ultimately, a clinical investigation would need to measure defined outcomes in appropriately diagnosed patients rather than assuming that results from isolated cells or animal models will translate directly.
Frequently Asked Questions
Does BCP reduce histamine release?
In a 2021 laboratory study, BCP reduced histamine release from rat peritoneal mast cells stimulated through a defined experimental pathway. Human MCAS outcomes were not measured.
Is BCP a mast-cell stabilizer?
Experimental findings suggest that BCP can inhibit mast-cell degranulation under certain laboratory conditions. Calling it an established clinical mast-cell stabilizer for MCAS would require supporting human studies.
Does beta-caryophyllene activate CB2?
Yes. A 2008 receptor study characterized beta-caryophyllene as a functional CB2 agonist. The later mast-cell study examined additional signaling pathways rather than establishing that CB2 caused all observed effects.
Can BCP prevent anaphylaxis?
A mouse study found reduced compound 48/80-induced anaphylaxis-like responses, but this does not demonstrate prevention of human anaphylaxis. Epinephrine remains the emergency treatment for anaphylaxis.
How is MCAS different from histamine intolerance?
MCAS is evaluated using systemic clinical episodes, objective evidence of mast-cell mediator release and treatment response. Histamine intolerance is a different, less clearly standardized concept often discussed in relation to food-derived histamine and gastrointestinal symptoms.
Have BCPlus products been tested in human MCAS trials?
The studies examined in this article do not establish clinical efficacy of a finished BCPlus formulation in people diagnosed with MCAS.
What the Research Reveals
Mast cells occupy an important position between the immune system and the tissues it protects.
The chemicals they release can influence the skin, digestive tract, lungs and circulation. Their activation is controlled by more than one biological pathway.
Beta-caryophyllene provides an interesting research tool because scientists have established its CB2 activity and separately observed changes in mast-cell degranulation, histamine release and intracellular signaling.
The most useful next step for this field is to determine which of those mechanisms can be reproduced in human experimental systems and whether they influence measurable clinical outcomes.
The resulting evidence may deepen our understanding of mast-cell regulation and the biology underlying allergic and pseudo-allergic responses.
Explore BCPlus Formulations
Blair Medical Group develops physician-formulated BCPlus products containing beta-caryophyllene in several delivery formats.
For readers interested in oral formulations, BCPlus Oral Liposomal Drops 60 mL provides current product-specific information.
The pharmacological findings discussed above concern beta-caryophyllene research and should be distinguished from clinical testing of a finished BCPlus formulation.
For broader background, explore BMG's articles on BCP and immune signaling, BCP and inflammation, and human beta-caryophyllene studies.
Scientific references
1. Pathak MP, et al. Crosstalk between AdipoR1/AdipoR2 and Nrf2/HO-1 signal pathways activated by β-caryophyllene suppressed the compound 48/80 induced pseudo-allergic reactions. Clin Exp Pharmacol Physiol. 2021;48:1523–1536. PMID 34314522. 2. Gertsch J, et al. Beta-caryophyllene is a dietary cannabinoid. PNAS. 2008;105:9099–9104. PMID 18574142. 3. Lee E, et al. Diagnosis and management of mast cell activation syndrome in Canada: a practical approach. Allergy Asthma Clin Immunol. 2025. PMID 41272881.
Source material: Mast Cell Activation Syndrome & Beta-Caryophyllene, Blair Medical Group Educational Library, ©2023.
Publisher: Blair Medical Group.





Comments